These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

230 related articles for article (PubMed ID: 31370843)

  • 1. PK/PD modeling of Ceftiofur Sodium against Haemophilus parasuis infection in pigs.
    Li XD; Chi SQ; Wu LY; Liu C; Sun T; Hong J; Chen X; Chen XG; Wang GS; Yu DJ
    BMC Vet Res; 2019 Aug; 15(1):272. PubMed ID: 31370843
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Integration of pharmacokinetic-pharmacodynamic for dose optimization of doxycycline against Haemophilus parasuis in pigs.
    Zhang L; Li Y; Wang Y; Sajid A; Ahmed S; Li X
    J Vet Pharmacol Ther; 2018 Oct; 41(5):706-718. PubMed ID: 29696661
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pharmacokinetics of tilmicosin in healthy pigs and in pigs experimentally infected with
    Zhang L; Zhao L; Liu Y; Liu J; Li X
    J Vet Sci; 2017 Dec; 18(4):431-437. PubMed ID: 28385011
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pharmacokinetic/pharmacodynamic (PK/PD) evaluation of tulathromycin against Haemophilus parasuis in an experimental neutropenic guinea pig model.
    Zhao Y; Guo LL; Fang B; Liu B
    PLoS One; 2018; 13(12):e0209177. PubMed ID: 30596709
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Optimal regimens based on PK/PD cutoff evaluation of ceftiofur against Actinobacillus pleuropneumoniae in swine.
    Sun D; Mi K; Hao H; Xie S; Chen D; Huang L
    BMC Vet Res; 2020 Sep; 16(1):366. PubMed ID: 32993661
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Epidemiological and PK/PD cutoff values determination and PK/PD-based dose assessment of gamithromycin against Haemophilus parasuis in piglets.
    Zhou YF; Bu MX; Liu P; Sun J; Liu YH; Liao XP
    BMC Vet Res; 2020 Mar; 16(1):81. PubMed ID: 32138735
    [TBL] [Abstract][Full Text] [Related]  

  • 7. PK/PD modelling of enrofloxacin against Glaesserella parasuis infection in pigs.
    Yang B; Li XD; Chen X; Hong J; Liu C; Zheng JP; Ou ZY; Yu DJ
    J Vet Pharmacol Ther; 2022 May; 45(3):291-300. PubMed ID: 35348230
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pharmacokinetic/pharmacodynamic evaluation of marbofloxacin in the treatment of Haemophilus parasuis and Actinobacillus pleuropneumoniae infections in nursery and fattener pigs using Monte Carlo simulations.
    Vilalta C; Giboin H; Schneider M; El Garch F; Fraile L
    J Vet Pharmacol Ther; 2014 Dec; 37(6):542-9. PubMed ID: 24903473
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Antimicrobial susceptibility of Haemophilus parasuis and Histophilus somni from pigs and cattle in Denmark.
    Aarestrup FM; Seyfarth AM; Angen Ø
    Vet Microbiol; 2004 Jun; 101(2):143-6. PubMed ID: 15172697
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Formulation of a rational dosage regimen of ceftiofur hydrochloride oily suspension by pharmacokinetic-pharmacodynamic (PK-PD) model for treatment of swine
    Luo W; Wang D; Qin H; Chen D; Pan Y; Qu W; Huang L; Xie S
    J Vet Sci; 2021 Nov; 22(6):e41. PubMed ID: 34854264
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pharmacokinetic and pharmacodynamic characterization of ceftiofur crystalline-free acid following subcutaneous administration in domestic goats.
    Waraich GS; Sidhu PK; Daundkar PS; Kaur G; Sharma SK
    J Vet Pharmacol Ther; 2017 Oct; 40(5):429-438. PubMed ID: 27943295
    [TBL] [Abstract][Full Text] [Related]  

  • 12. In vitro dynamic pharmacokinetic/pharmacodynamic(PK/PD) modeling and PK/PD cutoff of cefquinome against Haemophilus parasuis.
    Xiao X; Sun J; Chen Y; Huang RJ; Huang T; Qiao GG; Zhou YF; Liu YH
    BMC Vet Res; 2015 Feb; 11():33. PubMed ID: 25889187
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Inhibition of Haemophilus parasuis by berberine and proteomic studies of its mechanism of action.
    Jia Y; Hao C; Yang Q; Zhang W; Li G; Liu S; Hua X
    Res Vet Sci; 2021 Sep; 138():62-68. PubMed ID: 34111715
    [TBL] [Abstract][Full Text] [Related]  

  • 14. In vitro Dynamic Pharmacokinetic/Pharmacodynamic (PK/PD) study and COPD of Marbofloxacin against Haemophilus parasuis.
    Sun J; Xiao X; Huang RJ; Yang T; Chen Y; Fang X; Huang T; Zhou YF; Liu YH
    BMC Vet Res; 2015 Dec; 11():293. PubMed ID: 26626889
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effect of enrofloxacin on Haemophilus parasuis infection, disease and immune response.
    Macedo N; Cheeran MC; Rovira A; Holtcamp A; Torremorell M
    Vet Microbiol; 2017 Feb; 199():91-99. PubMed ID: 28110792
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A novel experimental intraperitoneal infection model for Haemophilus parasuis in neutropenic guinea pigs.
    Zhao YD; Liu BT; Guo LL; Shan H; Fang BH
    J Pharmacol Toxicol Methods; 2019; 95():27-35. PubMed ID: 30476621
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Antibacterial effect of Blumea balsamifera DC. essential oil against Haemophilus parasuis.
    He C; Yang P; Wang L; Jiang X; Zhang W; Liang X; Yin L; Yin Z; Geng Y; Zhong Z; Song X; Zou Y; Li L; Lv C
    Arch Microbiol; 2020 Nov; 202(9):2499-2508. PubMed ID: 32638056
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pharmacokinetic-pharmacodynamic modeling of tylosin against Streptococcus suis in pigs.
    Huang L; Zhang H; Li M; Ahmad I; Wang Y; Yuan Z
    BMC Vet Res; 2018 Oct; 14(1):319. PubMed ID: 30355326
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Investigation of Haemophilus parasuis from healthy pigs in China.
    Zhang P; Zhang C; Aragon V; Zhou X; Zou M; Wu C; Shen Z
    Vet Microbiol; 2019 Apr; 231():40-44. PubMed ID: 30955821
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Distribution of antimicrobial resistance among different serovars of Haemophilus parasuis isolates.
    Zhou X; Xu X; Zhao Y; Chen P; Zhang X; Chen H; Cai X
    Vet Microbiol; 2010 Feb; 141(1-2):168-73. PubMed ID: 19564084
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.